![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY
Department of Biochemistry, Trinity College, Dublin, Ireland (M.M.M.G., L.M.G., S.L., D.C.W., D.M.Z.); Dipartimento Farmaco Chimico Tecnologico, Universita'delgi Studi di Siena, Siena, Italy (G.C., V.N.); and Department of Hematology, Institute of Molecular Medicine, Trinity Centre, St. James's Hospital, Dublin, Ireland (M.L.)
Overexpression of the Bcl-2 proto-oncogene in tumor cells confers resistance against chemotherapeutic drugs. In this study, we describe how the novel pyrrolo-1,5-benzoxazepine compound 7-[{dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) selectively induces apoptosis in Bcl-2-overexpressing cancer cells, whereas it shows no cytotoxic effect on normal peripheral blood mononuclear cells. PBOX-6 overcomes Bcl-2-mediated resistance to apoptosis in chronic myelogenous leukemia (CML) K562 cells by the time- and dose-dependent phosphorylation and inactivation of antiapoptotic Bcl-2 family members Bcl-2 and Bcl-XL. PBOX-6 also induces Bcl-2 phosphorylation and apoptosis in wild-type T leukemia CEM cells and cells overexpressing Bcl-2. This is in contrast to chemotherapeutic agents such as etoposide, actinomycin D, and ultraviolet irradiation, whereby overexpression of Bcl-2 confers resistance against apoptosis. In addition, PBOX-6 induces Bcl-2 phosphorylation and apoptosis in wild-type Jurkat acute lymphoblastic leukemia cells and cells overexpressing Bcl-2. However, Jurkat cells containing a Bcl-2 triple mutant, whereby the principal Bcl-2 phosphorylation sites are mutated to alanine, demonstrate resistance against Bcl-2 phosphorylation and apoptosis. PBOX-6 also induces the early and transient activation of c-Jun NH2-terminal kinase (JNK) in CEM cells. Inhibition of JNK activity prevents Bcl-2 phosphorylation and apoptosis, implicating JNK in the upstream signaling pathway leading to Bcl-2 phosphorylation. Collectively, these findings identify Bcl-2 phosphorylation and inactivation as a critical step in the apoptotic pathway induced by PBOX-6 and highlight its potential as an effective antileukemic agent.
Address correspondence to: Dr. Daniela Zisterer, Department of Biochemistry, Trinity College, Dublin 2, Ireland. E-mail: dzistrer{at}tcd.ie
This article has been cited by other articles:
![]() |
F. T. Bane, J. H. Bannon, S. R. Pennington, G. Campaini, D. C. Williams, D. M. Zisterer, and M. M. Mc Gee The Microtubule-Targeting Agents, PBOX-6 [Pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and Paclitaxel, Induce Nucleocytoplasmic Redistribution of the Peptidyl-Prolyl Isomerases, Cyclophilin A and Pin1, in Malignant Hematopoietic Cells J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 38 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Greene, G. Campiani, M. Lawler, D. C. Williams, and D. M. Zisterer BubR1 Is Required for a Sustained Mitotic Spindle Checkpoint Arrest in Human Cancer Cells Treated with Tubulin-Targeting Pyrrolo-1,5-Benzoxazepines Mol. Pharmacol., February 1, 2008; 73(2): 419 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Greene, L. Kelly, V. Onnis, G. Campiani, M. Lawler, D. C. Williams, and D. M. Zisterer STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia Cells J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 288 - 297. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Mulligan, L. M. Greene, S. Cloonan, M. M. Mc Gee, V. Onnis, G. Campiani, C. Fattorusso, M. Lawler, D. C. Williams, and D. M. Zisterer Identification of Tubulin as the Molecular Target of Proapoptotic Pyrrolo-1,5-benzoxazepines Mol. Pharmacol., July 1, 2006; 70(1): 60 - 70. [Abstract] [Full Text] [PDF] |
||||